Healthcare · NYSE/NASDAQ: ABBV
AbbVie Inc.
Drug Manufacturers
Market Cap $350.00B
Verdict: High
Quality Scores
Multi-Bagger
72/100
Compounder Quality
85/100
Management Credibility
92/100
Governance
82/100
Cash Flow Quality
92/100
AI Summary
AbbVie Inc. has evolved from a single-product reliance on Humira into a diversified biopharmaceutical powerhouse despite significant accounting volatility and balance sheet leverage. The company successfully executed the acquisition of Allergan in 2020, which scaled revenues from $33B levels to over $54B (adjusted for pro-forma) and subsequently managed the Humira patent cliff (LOE) in 2023 with resilience. While GAAP net income has fluctuated wildly due to massive non-cash intangible amortization, litigation settlements, and IPR&D charges (especially in 2024), the cash flow generation…
Top Opportunities
- Extremely robust Cash Flow from Operations (OCF)
- Tier-1 R&D pipeline with Skyrizi and Rinvoq exceeding expectations
- Disciplined debt reduction post-Allergan acquisition
Top Risks
- Negative Shareholders Equity in 2025 due to capital allocation
- Heavy reliance on a few key blockbusters
- Significant biosimilar competition for Humira (US/EU)
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.